Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer.

Clinical use of the DiviTum TKa assay is expected to decrease traditional imaging and monitoring and may reduce the overall cost of managing mBC if it leads to clinical decisions to avoid futile therapy. Post-coverage, real-world monitoring of palliative therapies among post-menopausal mBC populations is needed to better categorize cost savings over time.